A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Tango Therapeutics, Inc.
Verastem, Inc.
GlaxoSmithKline
Novartis
Novartis
Servier
Sensome
Novartis
Amgen
Eli Lilly and Company
Pfizer
Hoffmann-La Roche
Eli Lilly and Company
Pfizer
Pfizer
Integro Theranostics
Pfizer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Merck Sharp & Dohme LLC
Pheon Therapeutics
Eli Lilly and Company
Teclison Ltd.
AstraZeneca
Bristol-Myers Squibb
ArriVent BioPharma, Inc.
Achieve Life Sciences
Iovance Biotherapeutics, Inc.
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Boehringer Ingelheim
Zymeworks BC Inc.
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Hoffmann-La Roche
Tango Therapeutics, Inc.
Bristol-Myers Squibb
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Endowave Ltd.
Pfizer
Revolution Medicines, Inc.
Genmab
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
Novartis
Bristol-Myers Squibb
Taiho Oncology, Inc.
Intuitive Surgical